BioSpace News Archive

Prevalence of insomnia has recorded a tremendous surge in the recent past, however development of an effective treatment procedure for insomnia has not yet been realized.

The global market for human microbiome is projected to showcase a considerable potential in the coming years of the forecast period.

Unhealthy eating habits and hectic lifestyles have led to increased number of chronic diseases such as diabetes.

Ping An Insurance Company of China, Ltd. is pleased to announce that agreements have been signed with Shionogi Company Ltd. "), a wholly owned subsidiary of Shionogi & Co., Ltd. to launch joint ventures in Shanghai and Hong Kong, namely Ping An-Shionogi Co., Ltd.[1] and Ping An-Shionogi Limited[2]. The establishment of the joint ventures will enhance the level of health and medical care service in China, in line with Ping An’s healthcare ecosystem strategy.

Aiming to provide better health management services to lung cancer patients, “Cloud Enabled Lung Cancer Care by Great Doctors” was officially launched in Shanghai on July 25, 2020.

Axonics Modulation Technologies, Inc. announced completion of 2-year follow-ups and topline clinical results from its ARTISAN-SNM pivotal study that was conducted to evaluate the safety and efficacy of the Axonics r-SNM System®.

MediciNova, Inc. announced an agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine using BC-PIV, a human parainfluenza virus type 2 vector developed by BioComo and Tetsuya Nosaka, M.D., Ph.D., professor of the Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine.

Aerie Pharmaceuticals, Inc. reported positive topline results for the Company’s Phase 2 clinical trial evaluating AR-1105 in patients with macular edema associated with retinal vein occlusion.

Emergent BioSolutions Inc. announced that it has signed an agreement to provide contract development and manufacturing services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222.

Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust